

# Peter J M Openshaw

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5851088/publications.pdf>

Version: 2024-02-01

248  
papers

24,265  
citations

8172

76  
h-index

9854

141  
g-index

340  
all docs

340  
docs citations

340  
times ranked

34693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Features of 20% 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. <i>BMJ, The</i> , 2020, 369, m1985.	3.0	2,474
2	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
3	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021, 591, 92-98.	13.7	1,014
4	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. <i>BMJ, The</i> , 2020, 370, m3339.	3.0	779
5	IFITM3 restricts the morbidity and mortality associated with influenza. <i>Nature</i> , 2012, 484, 519-523.	13.7	668
6	Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations.. <i>Journal of Experimental Medicine</i> , 1995, 182, 1357-1367.	4.2	547
7	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541
8	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. <i>BMJ, The</i> , 2020, 370, m3249.	3.0	478
9	Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.. <i>Journal of Experimental Medicine</i> , 1988, 168, 1163-1168.	4.2	454
10	Reversibility of T helper 1 and 2 populations is lost after long-term stimulation.. <i>Journal of Experimental Medicine</i> , 1996, 183, 901-913.	4.2	401
11	Bronchiolitis. <i>Lancet, The</i> , 2006, 368, 312-322.	6.3	381
12	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. <i>Lancet Infectious Diseases, The</i> , 2018, 18, e295-e311.	4.6	355
13	Distinct types of lung disease caused by functional subsets of antiviral T cells.. <i>Journal of Experimental Medicine</i> , 1994, 179, 81-89.	4.2	318
14	Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 717-725.	5.2	312
15	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. <i>Nature Medicine</i> , 2022, 28, 1031-1041.	15.2	281
16	Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. <i>European Journal of Immunology</i> , 2001, 31, 2566-2573.	1.6	274
17	Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. <i>Clinical Microbiology Reviews</i> , 2005, 18, 541-555.	5.7	263
18	Age at First Viral Infection Determines the Pattern of T Cell-mediated Disease during Reinfection in Adulthood. <i>Journal of Experimental Medicine</i> , 2002, 196, 1381-1386.	4.2	237

#	ARTICLE	IF	CITATIONS
19	RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. <i>Nature Communications</i> , 2015, 6, 10224.	5.8	237
20	Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S577-S583.	1.9	231
21	CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. <i>European Journal of Immunology</i> , 1997, 27, 3341-3349.	1.6	222
22	Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. <i>International Immunology</i> , 1992, 4, 493-500.	1.8	220
23	Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1040-1049.	2.5	216
24	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	3.4	216
25	Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). <i>Thorax</i> , 2010, 65, 645-651.	2.7	214
26	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.5	204
27	Flow cytometric measurement of intracellular cytokines. <i>Journal of Immunological Methods</i> , 2000, 243, 107-124.	0.6	203
28	Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100186.	3.0	191
29	A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. <i>Nature Medicine</i> , 2006, 12, 905-907.	15.2	187
30	Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development. <i>Journal of Virology</i> , 2008, 82, 4441-4448.	1.5	185
31	SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. <i>Lancet</i> , The, 2022, 399, 1463-1464.	6.3	178
32	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	13.7	174
33	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
34	The microbiology of asthma. <i>Nature Reviews Microbiology</i> , 2012, 10, 459-471.	13.6	170
35	Respiratory Syncytial Virus, Airway Inflammation, and FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 871-876.	2.5	169
36	Protective and Harmful Immunity to RSV Infection. <i>Annual Review of Immunology</i> , 2017, 35, 501-532.	9.5	169

#	ARTICLE	IF	CITATIONS
37	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	161
38	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 349-359.	5.2	161
39	Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. <i>Mucosal Immunology</i> , 2012, 5, 161-172.	2.7	156
40	Immunity to RSV in Early-Life. <i>Frontiers in Immunology</i> , 2014, 5, 466.	2.2	154
41	CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. <i>Clinical and Experimental Immunology</i> , 2008, 88, 527-536.	1.1	147
42	Immunity and Immunopathology to Respiratory Syncytial Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 152, S59-S62.	2.5	143
43	Latency and Persistence of Respiratory Syncytial Virus Despite T Cell Immunity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 801-805.	2.5	143
44	Immunopathogenesis of vaccine-enhanced RSV disease. <i>Vaccine</i> , 2001, 20, S27-S31.	1.7	140
45	Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia. <i>Journal of Experimental Medicine</i> , 1998, 187, 1921-1926.	4.2	137
46	Microbes and mucosal immune responses in asthma. <i>Lancet</i> , The, 2013, 381, 861-873.	6.3	134
47	CD25 <sup>+</sup> Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2010, 84, 8790-8798.	1.5	133
48	Maternal immunisation: collaborating with mother nature. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e197-e208.	4.6	133
49	Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. <i>Journal of Virology</i> , 1992, 66, 2102-2110.	1.5	128
50	Influenza Virus Lung Infection Protects from Respiratory Syncytial Virus-Induced Immunopathology. <i>Journal of Experimental Medicine</i> , 2000, 192, 1317-1326.	4.2	127
51	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	6.0	124
52	Alpha/Beta Interferon Receptor Signaling Amplifies Early Proinflammatory Cytokine Production in the Lung during Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2014, 88, 6128-6136.	1.5	122
53	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711.	5.2	122
54	Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. <i>Nature Immunology</i> , 2018, 19, 625-635.	7.0	119

#	ARTICLE	IF	CITATIONS
55	Changes in rib cage geometry during childhood.. Thorax, 1984, 39, 624-627.	2.7	117
56	IL-10 Regulates Viral Lung Immunopathology during Acute Respiratory Syncytial Virus Infection in Mice. PLoS ONE, 2012, 7, e32371.	1.1	116
57	Antiviral B cell and T cell immunity in the lungs. Nature Immunology, 2015, 16, 18-26.	7.0	115
58	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respiratory Medicine, the, 2020, 8, 822-830.	5.2	110
59	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	6.3	110
60	The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. Journal of Virology, 1990, 64, 1683-1689.	1.5	110
61	Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatric Infectious Disease Journal, 2003, 22, S58-S65.	1.1	107
62	The Role of T Cells in the Enhancement of Respiratory Syncytial Virus Infection Severity during Adult Reinfection of Neonatally Sensitized Mice. Journal of Virology, 2008, 82, 4115-4124.	1.5	107
63	Role of CCL5 (RANTES) in Viral Lung Disease. Journal of Virology, 2006, 80, 8151-8157.	1.5	106
64	COVID-19: Lessons from SARS and MERS. European Journal of Immunology, 2020, 50, 308-311.	1.6	105
65	Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology. Journal of Experimental Medicine, 2001, 193, 785-792.	4.2	104
66	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
67	Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science, 2020, 370, .	6.0	100
68	Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus. Journal of Immunology, 2002, 169, 2210-2214.	0.4	99
69	Differential Chemokine Expression following Respiratory Virus Infection Reflects Th1- or Th2-Biased Immunopathology. Journal of Virology, 2006, 80, 4521-4527.	1.5	98
70	Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax, 2019, 74, 986-993.	2.7	96
71	Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses. Journal of Immunology, 2001, 166, 1106-1113.	0.4	94
72	Protective and dysregulated T cell immunity in RSV infection. Current Opinion in Virology, 2013, 3, 468-474.	2.6	91

#	ARTICLE	IF	CITATIONS
73	Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2987-2992.	3.3	90
74	Immunopathological mechanisms in respiratory syncytial virus disease. <i>Seminars in Immunopathology</i> , 1995, 17, 187-201.	4.0	89
75	Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. <i>Vaccine</i> , 1993, 11, 431-437.	1.7	86
76	Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. <i>Lancet, The</i> , 2020, 395, 42-52.	6.3	85
77	Long-term persistence and reactivation of T cell memory in the lung of mice infected with respiratory syncytial virus. <i>European Journal of Immunology</i> , 2001, 31, 2574-2582.	1.6	84
78	Regulatory T Cells Prevent Th2 Immune Responses and Pulmonary Eosinophilia during Respiratory Syncytial Virus Infection in Mice. <i>Journal of Virology</i> , 2013, 87, 10946-10954.	1.5	84
79	Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. <i>Journal of Virology</i> , 2014, 88, 13269-13283.	1.5	84
80	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 8-9.	4.6	82
81	Pulmonary defences to acute respiratory infection. <i>British Medical Bulletin</i> , 2002, 61, 1-12.	2.7	81
82	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine, the</i> , 2021, 9, 773-785.	5.2	78
83	Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. <i>Thorax</i> , 2012, 67, 709-717.	2.7	76
84	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. <i>Lancet, The</i> , 2021, 398, 1037-1038.	6.3	75
85	The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S563-S569.	1.9	74
86	Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. <i>Lancet Infectious Diseases, The</i> , 2017, 17, e223-e234.	4.6	73
87	Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1074-1084.	2.5	73
88	Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. <i>European Respiratory Journal</i> , 2002, 20, 376-382.	3.1	71
89	IL-12-Activated NK Cells Reduce Lung Eosinophilia to the Attachment Protein of Respiratory Syncytial Virus But Do Not Enhance the Severity of Illness in CD8 T Cell-Immunodeficient Conditions. <i>Journal of Immunology</i> , 2000, 165, 7109-7115.	0.4	68
90	RSV-Induced Bronchial Epithelial Cell PD-L1 Expression Inhibits CD8+ T Cell Nonspecific Antiviral Activity. <i>Journal of Infectious Diseases</i> , 2011, 203, 85-94.	1.9	66

#	ARTICLE	IF	CITATIONS
91	Anaphylactic sensitization to aeroantigen during respiratory virus infection. <i>Clinical and Experimental Allergy</i> , 1998, 28, 1501-1508.	1.4	65
92	Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases. <i>Nature Communications</i> , 2019, 10, 2887.	5.8	65
93	Mouse $\gamma\delta$ TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to $\alpha\beta$ TCR+NK1.1+ thymocytes. <i>European Journal of Immunology</i> , 1996, 26, 1424-1429.	1.6	63
94	Pulmonary $\gamma\delta$ T Cells Have Proinflammatory and Antiviral Effects in Viral Lung Disease. <i>Journal of Immunology</i> , 2009, 182, 1174-1181.	0.4	63
95	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. <i>European Journal of Immunology</i> , 2001, 31, 1438-1446.	1.6	60
96	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. <i>JCI Insight</i> , 2017, 2, e91868.	2.3	59
97	Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. <i>Journal of Pediatrics</i> , 1998, 133, 272-274.	0.9	57
98	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	56
99	Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. <i>Journal of Virology</i> , 2018, 92, .	1.5	55
100	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S570-S576.	1.9	54
101	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	5.8	54
102	Role of CCL11 in Eosinophilic Lung Disease during Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2005, 79, 2050-2057.	1.5	53
103	Nosocomial Pandemic (H1N1) 2009, United Kingdom, 2009-2010. <i>Emerging Infectious Diseases</i> , 2011, 17, 592-598.	2.0	53
104	Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. <i>European Respiratory Journal</i> , 2011, 38, 401-408.	3.1	52
105	Toward unified molecular surveillance of RSV: A proposal for genotype definition. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 274-285.	1.5	52
106	The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. <i>Respiratory Research</i> , 2005, 6, 70.	1.4	51
107	Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. <i>Clinical and Experimental Allergy</i> , 2008, 38, 1016-1024.	1.4	51
108	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020, 12, 1164.	1.5	51

#	ARTICLE	IF	CITATIONS
109	The Chemokine MIP1 $\alpha$ /CCL3 Determines Pathology in Primary RSV Infection by Regulating the Balance of T Cell Populations in the Murine Lung. PLoS ONE, 2010, 5, e9381.	1.1	51
110	Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells. Journal of Virology, 2010, 84, 4073-4082.	1.5	50
111	Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunology, 2020, 13, 566-573.	2.7	50
112	Pre-Admission Statin Use and In-Hospital Severity of 2009 Pandemic Influenza A(H1N1) Disease. PLoS ONE, 2011, 6, e18120.	1.1	49
113	Emerging drugs for respiratory syncytial virus infection. Expert Opinion on Emerging Drugs, 2009, 14, 207-217.	1.0	48
114	Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood, 2010, 115, 396-407.	0.6	47
115	Influenza burden, prevention, and treatment in asthma—A scoping review by the <sc>EAACI</sc> Influenza in asthma task force. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1151-1181.	2.7	47
116	Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. European Respiratory Journal, 2013, 41, 824-831.	3.1	46
117	Childhood infections, the developing immune system, and the origins of asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 1275-1277.	1.5	45
118	Crossing barriers: infections of the lung and the gut. Mucosal Immunology, 2009, 2, 100-102.	2.7	45
119	Current concepts and progress in RSV vaccine development. Expert Review of Vaccines, 2014, 13, 333-344.	2.0	44
120	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	1.9	43
121	Antiviral Immune Responses and Lung Inflammation after Respiratory Syncytial Virus Infection. Proceedings of the American Thoracic Society, 2005, 2, 121-125.	3.5	43
122	Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Are Dependent on Cells of the Innate Immune System. Journal of Virology, 2014, 88, 604-611.	1.5	43
123	Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation. Journal of Allergy and Clinical Immunology, 2014, 133, 827-835.e3.	1.5	43
124	Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. Trends in Microbiology, 2021, 29, 648-662.	3.5	43
125	Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection. Journal of Clinical Investigation, 2019, 130, 523-538.	3.9	42
126	IL-9 Regulates Pathology during Primary and Memory Responses to Respiratory Syncytial Virus Infection. Journal of Immunology, 2009, 183, 7006-7013.	0.4	41



#	ARTICLE	IF	CITATIONS
127	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 770-772.	4.6	40
128	Attenuated <i>Bordetella pertussis</i> Vaccine Protects against Respiratory Syncytial Virus Disease via an IL-17-Dependent Mechanism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 194-202.	2.5	38
129	Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. <i>Vaccine</i> , 2004, 23, 215-221.	1.7	37
130	Genetic Susceptibility to the Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Is MHC Dependent. <i>Journal of Immunology</i> , 2010, 185, 5384-5391.	0.4	36
131	Human microbial challenge: the ultimate animal model. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 903-905.	4.6	36
132	Neonatal antibody responses are attenuated by interferon- $\gamma$ produced by NK and T cells during RSV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5576-5581.	3.3	36
133	Predominance of heterosubtypic $\text{IFN-}\gamma$ -secreting effector memory T cells in pandemic H1N1 naive adults. <i>European Journal of Immunology</i> , 2012, 42, 2913-2924.	1.6	34
134	Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. <i>Obesity</i> , 2021, 29, 1223-1230.	1.5	34
135	Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	32
136	Potential therapeutic implications of new insights into respiratory syncytial virus disease. <i>Respiratory Research</i> , 2002, 3, S15-20.	1.4	31
137	Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. <i>Microbes and Infection</i> , 2004, 6, 1049-1055.	1.0	30
138	Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from inter-pandemic community-acquired pneumonia in adults. <i>Thorax</i> , 2011, 66, 247-252.	2.7	30
139	Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 481-492.	2.5	30
140	The protective effect of childhood infections. <i>BMJ: British Medical Journal</i> , 2001, 322, 376-377.	2.4	29
141	Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis. <i>Journal of Infectious Diseases</i> , 2017, 215, 1240-1244.	1.9	29
142	Virally Delivered Cytokines Alter the Immune Response to Future Lung Infections. <i>Journal of Virology</i> , 2007, 81, 13105-13111.	1.5	28
143	Delivery of Cytokines by Recombinant Virus in Early Life Alters the Immune Response to Adult Lung Infection. <i>Journal of Virology</i> , 2010, 84, 5294-5302.	1.5	28
144	Preexposure to CpG Protects against the Delayed Effects of Neonatal Respiratory Syncytial Virus Infection. <i>Journal of Virology</i> , 2012, 86, 10456-10461.	1.5	28

#	ARTICLE	IF	CITATIONS
145	Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life. <i>Nature Communications</i> , 2021, 12, 4957.	5.8	25
146	Potential Mechanisms Causing Delayed Effects of Respiratory Syncytial Virus Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, S10-S13.	2.5	24
147	Prior Exposure to Live <i>Mycobacterium bovis</i> BCG Decreases <i>Cryptococcus neoformans</i> -Induced Lung Eosinophilia in a Gamma Interferon-Dependent Manner. <i>Infection and Immunity</i> , 2003, 71, 3384-3391.	1.0	24
148	Contribution of cytokines to pathology and protection in virus infection. <i>Current Opinion in Virology</i> , 2011, 1, 184-195.	2.6	24
149	Issues in vaccinology: Present challenges and future directions. <i>European Journal of Immunology</i> , 2017, 47, 2017-2025.	1.6	24
150	Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database. <i>European Respiratory Journal</i> , 2020, 56, 2001809.	3.1	24
151	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , 2022, 77, 606-615.	2.7	24
152	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24
153	Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 694-703.e12.	1.5	23
154	Respiratory syncytial virus and wheeze. <i>Lancet</i> , The, 1999, 354, 1997-1998.	6.3	22
155	What does the peripheral blood tell you in SARS?. <i>Clinical and Experimental Immunology</i> , 2004, 136, 11-12.	1.1	22
156	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. <i>European Respiratory Journal</i> , 2019, 54, 1900949.	3.1	22
157	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2022, 141, 147-173.	1.8	22
158	Title is missing!. <i>Pediatric Infectious Disease Journal</i> , 2003, 22, S58-S65.	1.1	21
159	Respiratory syncytial virus and other pneumoviruses: a review of the international symposium "RSV 2003". <i>Virus Research</i> , 2004, 106, 1-13.	1.1	21
160	A High-Fat Diet Increases Influenza A Virus-Associated Cardiovascular Damage. <i>Journal of Infectious Diseases</i> , 2020, 222, 820-831.	1.9	21
161	COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol. <i>European Respiratory Journal</i> , 2021, 58, 2100929.	3.1	21
162	Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. <i>Emerging Infectious Diseases</i> , 2021, 27, 1-9.	2.0	20

#	ARTICLE	IF	CITATIONS
163	The Mouse Model of Respiratory Syncytial Virus Disease. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 359-369.	0.7	20
164	Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. <i>Journal of General Virology</i> , 2004, 85, 3017-3026.	1.3	19
165	Poly(lactide-co-glycolide) (PLG) microparticles modify the immune response to DNA vaccination. <i>Vaccine</i> , 2008, 26, 753-761.	1.7	19
166	Benefit and harm from immunity to respiratory syncytial virus. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 687-694.	1.3	19
167	Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort. <i>BMC Infectious Diseases</i> , 2021, 21, 717.	1.3	19
168	Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness. <i>PLoS ONE</i> , 2015, 10, e0135363.	1.1	19
169	Respiratory Syncytial Virus-associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries. <i>Journal of Infectious Diseases</i> , 2022, 226, S22-S28.	1.9	19
170	An improved protocol for measuring cytotoxic T cell activity in anatomic compartments with low cell numbers. <i>Journal of Immunological Methods</i> , 2001, 257, 155-161.	0.6	17
171	The Helminth-Derived Immunomodulator AvCystatin Reduces Virus Enhanced Inflammation by Induction of Regulatory IL-10+ T Cells. <i>PLoS ONE</i> , 2016, 11, e0161885.	1.1	17
172	Reply to Rook. <i>Trends in Immunology</i> , 2000, 21, 249-250.	7.5	16
173	Innate-like Gene Expression of Lung-Resident Memory CD8 <sup>+</sup> T Cells during Experimental Human Influenza: A Clinical Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 826-841.	2.5	16
174	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021, 12, 5125.	5.8	16
175	Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner?. <i>Current Opinion in Microbiology</i> , 1999, 2, 410-414.	2.3	15
176	Development of vaccines against common colds. <i>British Medical Bulletin</i> , 2002, 62, 99-111.	2.7	15
177	Increased aeroallergen-specific interleukin-4-producing T cells in asthmatic adults. <i>Clinical and Experimental Allergy</i> , 2002, 32, 1739-1744.	1.4	15
178	OX40 Ligand and Programmed Cell Death 1 Ligand 2 Expression on Inflammatory Dendritic Cells Regulates CD4 T Cell Cytokine Production in the Lung during Viral Disease. <i>Journal of Immunology</i> , 2012, 188, 1647-1655.	0.4	14
179	Comparison of CATs, CURB-65 and PMEWS as Triage Tools in Pandemic Influenza Admissions to UK Hospitals: Case Control Analysis Using Retrospective Data. <i>PLoS ONE</i> , 2012, 7, e34428.	1.1	14
180	The Comparative Clinical Course of Pregnant and Non-Pregnant Women Hospitalised with Influenza A(H1N1)pdm09 Infection. <i>PLoS ONE</i> , 2012, 7, e41638.	1.1	14

#	ARTICLE	IF	CITATIONS
181	Infections prevent the development of asthma—true, false or both?. <i>Journal of the Royal Society of Medicine</i> , 1999, 92, 495-499.	1.1	13
182	Using correlates to accelerate vaccinology. <i>Science</i> , 2022, 375, 22-23.	6.0	13
183	Mucosal Immune Responses to Respiratory Syncytial Virus. <i>Cells</i> , 2022, 11, 1153.	1.8	13
184	Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. <i>Microbes and Infection</i> , 2004, 6, 666-675.	1.0	12
185	Live Attenuated <i>B. pertussis</i> BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses. <i>PLoS ONE</i> , 2014, 9, e100166.	1.1	12
186	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. <i>Scientific Reports</i> , 2022, 12, 6843.	1.6	12
187	Impact of the 2009 influenza pandemic. <i>Thorax</i> , 2010, 65, 471-472.	2.7	11
188	Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. <i>Mucosal Immunology</i> , 2013, 6, 704-717.	2.7	11
189	Antivirals for influenza: where now for clinical practice and pandemic preparedness?. <i>Lancet</i> , The, 2014, 384, 386-387.	6.3	11
190	Effect of ethnicity on care pathway and outcomes in patients hospitalized with influenza A(H1N1)pdm09 in the UK. <i>Epidemiology and Infection</i> , 2015, 143, 1129-1138.	1.0	11
191	Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S666-S671.	1.9	11
192	Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. <i>Journal of Infectious Diseases</i> , 2020, 222, S584-S591.	1.9	10
193	Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe—results from the PED-MERMAIDS multicentre case-control study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000887.	1.2	10
194	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e055435.	0.8	10
195	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac179.	0.4	10
196	Clonal hematopoiesis is not significantly associated with COVID-19 disease severity. <i>Blood</i> , 2022, 140, 1650-1655.	0.6	10
197	Partners in crime: co-infections in the developing world. <i>Clinical and Experimental Immunology</i> , 2000, 122, 296-299.	1.1	9
198	Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. <i>Mucosal Immunology</i> , 2010, 3, 422-424.	2.7	9

#	ARTICLE	IF	CITATIONS
199	Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). <i>Journal of Infectious Diseases</i> , 2020, 222, S658-S665.	1.9	9
200	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. <i>The Lancet Healthy Longevity</i> , 2022, 3, e405-e416.	2.0	9
201	Vaccines in the Prevention of Viral Pneumonia. <i>Clinics in Chest Medicine</i> , 2017, 38, 155-169.	0.8	8
202	Biphasic activation of complement and fibrinolysis during the human nasal allergic response. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1892-1895.e6.	1.5	8
203	The 1918 Influenza Pandemic: one hundred years of progress, but where now?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 588-589.	5.2	8
204	OMIP-062: A 14-Color, 16-Antibody Panel for Immunophenotyping Human Innate Lymphoid, Myeloid and T Cells in Small Volumes of Whole Blood and Pediatric Airway Samples. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1231-1235.	1.1	8
205	Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 342-345.e7.	1.5	8
206	Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 167, 803-820.	1.1	8
207	Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. <i>GigaScience</i> , 2022, 11, .	3.3	8
208	A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	7
209	RSV bronchiolitis, $\gamma\delta$ T cells and asthma: are they linked?. <i>Clinical and Experimental Immunology</i> , 2003, 131, 197-198.	1.1	6
210	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. <i>Progress in Preventive Medicine (New York, N Y)</i> , 2017, 2, e006.	0.7	6
211	Vaccination policies in Europe: Common goals, diverse approaches and public doubts. <i>European Journal of Immunology</i> , 2018, 48, 10-12.	1.6	6
212	Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration. <i>ESMO Open</i> , 2020, 5, e000825.	2.0	6
213	Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus. <i>Frontiers in Immunology</i> , 2022, 13, 807104.	2.2	6
214	IFITM3 restricts the morbidity and mortality associated with influenza. <i>International Journal of Infectious Diseases</i> , 2012, 16, e79.	1.5	5
215	A Gene Expression Signature for RSV: Clinical Implications and Limitations. <i>PLoS Medicine</i> , 2013, 10, e1001550.	3.9	5
216	An Evaluation of Community Assessment Tools (CATs) in Predicting Use of Clinical Interventions and Severe Outcomes during the A(H1N1)pdm09 Pandemic. <i>PLoS ONE</i> , 2013, 8, e75384.	1.1	5

#	ARTICLE	IF	CITATIONS
217	RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel. <i>Immunity</i> , 2017, 46, 171-173.	6.6	4
218	Resilience of the respiratory microbiome in controlled adult RSV challenge study. <i>European Respiratory Journal</i> , 2022, 59, 2101932.	3.1	4
219	Inhaled corticosteroids: not just for asthma, but for COVID-19?. <i>Lancet Respiratory Medicine</i> , 2022, 10, 526-527.	5.2	4
220	MHC and antigen presentation. <i>Trends in Immunology</i> , 1989, 10, 396-397.	7.5	3
221	Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. <i>Journal of Viral Hepatitis</i> , 2005, 12, 604-608.	1.0	3
222	A New Role for CXCL4 in Respiratory Syncytial Virus Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 648-649.	2.5	3
223	COVID-19 and beyond: A call for action and audacious solidarity to all the citizens and nations, it is humanity's fight. <i>F1000Research</i> , 0, 9, 1130.	0.8	3
224	Severe Influenza: Clinical Features and Treatment Options. <i>Current Respiratory Medicine Reviews</i> , 2012, 8, 208-227.	0.1	3
225	Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda. <i>Journal of Infectious Diseases</i> , 2022, 226, S130-S134.	1.9	3
226	Vaccines for the prevention of respiratory viral infections: problems and current status. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 681-689.	1.9	2
227	Men and Women in Immunology: Closing the gap on gender parity?. <i>European Journal of Immunology</i> , 2018, 48, 1776-1779.	1.6	2
228	Beneficial and Harmful Immune Responses in the Respiratory Tract. , 1996, , 449-457.		2
229	<sup>1</sup> H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization. <i>Analytical Chemistry</i> , 2022, 94, 6919-6923.	3.2	2
230	Controlled Human Infection Challenge Studies with RSV. <i>Current Topics in Microbiology and Immunology</i> , 2022, , .	0.7	2
231	Response from Openshaw. <i>Trends in Microbiology</i> , 1994, 2, 149-150.	3.5	1
232	Where is SARS now?. <i>Thorax</i> , 2003, 58, 650-651.	2.7	1
233	T cells take the inside track. <i>Nature Medicine</i> , 2006, 12, 614-615.	15.2	1
234	Neuraminidase inhibitors for influenza complications—Authors' reply. <i>Lancet</i> , 2014, 384, 1261-1262.	6.3	1

#	ARTICLE	IF	CITATIONS
235	The Effect of Vitamin D Supplementation on Mucosal IL-5, MMP9 and Cathelicidin after Nasal Allergen Challenge with Grass Pollen. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB73.	1.5	1
236	The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1340-1342.	2.5	1
237	LSC Abstract "The AsthmaMap: Towards a community-driven reconstruction of asthma-relevant pathways and networks. , 2016, , .		1
238	Enhanced <i>in vivo</i> mucosal interferon and chemokine responses to a single stranded RNA analogue (R848) in participants with asthma. , 2019, , .		1
239	Susan Elizabeth Openshaw (née Scott Stokes). <i>BMJ: British Medical Journal</i> , 2008, 336, 621.6-621.	2.4	0
240	Doctors accepting flu vaccination is the sensible and responsible choice. <i>BMJ: British Medical Journal</i> , 2011, 343, d7199-d7199.	2.4	0
241	How should influenza be treated? Focus on antivirals. <i>Vaccine</i> , 2015, 33, 7033-7036.	1.7	0
242	Activation of the Complement, Coagulation and Fibrinolysis Pathways after Nasal Allergen Challenge. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB384.	1.5	0
243	S68...Phase 1 trial of an intranasal respiratory syncytial virus (rsv) subunit candidate vaccine: safety results from the muc-syngem study. , 2017, , .		0
244	A41...Deep sequencing of respiratory syncytial virus links viral diversity to disease severity. <i>Virus Evolution</i> , 2019, 5, .	2.2	0
245	Animal Models of Viral Respiratory Infections. , 2003, , .		0
246	Functional Characterisation of Alloreactive T-Cells Identifies CD25 and CD71 as the Optimal Targets for Allodepletion Strategies.. <i>Blood</i> , 2007, 110, 2183-2183.	0.6	0
247	Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation. , 2016, , .		0
248	The role of innate lymphoid cells in early life lung infection. , 2018, , .		0